ARCHIVES

DCT Board Sends Letter Opposing Bill Requiring Research On RU 486

This article is from The Cancer Letter archive.

Vol. 18 No. 44 | November 13, 1992

Download PDF Visit The Full Archive

Related Articles

FDA to refer false statements by regulated companies to SEC.

February 27, 2004

NCI apologize For Mismanagement Of NSABP, Says Fisher Resisted Criticism

April 22, 1994

Funding Opportunities: CAM Research Center Applications Sought.

January 3, 2003

DCT Advisors Okay PA In Imaging Patters Of Care RFA; Contracts

March 5, 1993

FDA Approves Lapatinib For Advanced Breast Cancer

March 30, 2007

NCAB Committee To Propose Event Marking Cancer Act

August 2, 1991